Eversana Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Eversana Pharmaceutical Import Records from India — 12 Products, $27.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eversana — Pharmaceutical Importer Profile (2026) | 12 Products, $27.6M Trade | TransData Nexus

Eversana

Pharmaceutical Importer · United States · Cardiovascular Focus · $27.6M Total Trade · DGFT Verified

Eversana is a pharmaceutical importer based in United States with a total trade value of $27.6M across 12 products in 9 therapeutic categories. Based on 552 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eversana sources from 20 verified Indian suppliers, with Zydus Lifesciences Limited accounting for 37.6% of imports.

Eversana — Import Portfolio & Supplier Network

Eversana import network — 12 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eversana?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$133.6M	3,763	37.6%
Intas Pharmaceuticals Limited	$66.9M	2,025	18.8%
Cadila Healthcare Limited

What Formulations Does Eversana Import?

Formulation	Value	Ships
Pharmaceutical medicine for human use	$3.7M	99
Pharmaceutical medicine for human use	$1.9M	56
Pharmaceutical medicine for human use	$1.9M	49
Pharmaceutical medicine for human use	$1.9M	49
Pharma medicine for human	$1.8M	51
Mesalamine delayed release tablets 1.2	$1.8M	35
Pharmaceutical medicine for human use	$1.7M	40
Tamsulosin hcl CAPS USP 0.4MG	$1.6M	32
Ketorolac tromethamine injection USP 30MG/ML (30MG/ML)	$1.6M	32
Tamsulosin hcl CAPS USP 0.4 MG	$1.5M	30
Pharma medicine for human	$1.5M	39
Ketorolac tromethamine injection USP 30MG/ML 30MG/ML	$1.4M	29
Pharmaceutical drugs and medicine-	$1.4M	32
Oseltamivir phosphate for oral	$1.4M	27
Pharma drugs & medi tacrolimus cap 1 MG	$1.3M	30

Eversana imports 4,212 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 12 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Heparin	Cardiovascular	$13.4M	268	3.8%	4
2	Enoxaparin	Cardiovascular	$3.5M	70	1.7%	5
3	Syringe	Medical Devices & Diagnostics	$3.5M	70	1.9%	7
4	Vancomycin	Antibiotics	$2.1M	42	2.3%	3
5	Sodium	Nutritional Supplements	$1.1M	23	0.3%	16
6	Furosemide	Diuretics	$1.0M	20	1.4%	16
7	Methylprednisolone	Corticosteroids	$650.0K	13	2.2%	4
8	Prednisolone	Respiratory	$650.0K	13	0.7%	11
9	Clindamycin	Antibiotics	$600.0K	12	0.7%	16
10	Levothyroxine	Diabetes & Endocrine	$550.0K	11	0.7%	9
11	Ketorolac	Analgesics & Antipyretics	$350.0K	7	0.3%	19
12	Diltiazem	Cardiovascular	$150.0K	3	0.8%	20

Eversana imports 12 pharmaceutical products across 9 categories into United States totaling $27.6M.

Eversana — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eversana is a leading independent provider of global services to the life sciences industry, offering integrated solutions that span all stages of the product lifecycle. Founded in 1995 and headquartered in Chicago, Illinois, the company serves over 670 organizations, including both innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Eversana's comprehensive suite of services includes integrated commercial models, patient services, field deployment solutions, market access strategies, pricing and revenue management, medical affairs, and data and analytics. The company operates over 25 locations across North America, Europe, and Asia Pacific, employing a team of more than 6,000 professionals.

2Distribution Network

Eversana's distribution network is extensive, with over 25 locations across North America, Europe, and Asia Pacific. This global presence enables the company to offer comprehensive commercialization services to pharmaceutical, medical device, and biotech companies worldwide.

3Industry Role

In the United States pharmaceutical supply chain, Eversana functions as a comprehensive commercialization partner rather than a traditional wholesaler or distributor. The company's integrated services support pharmaceutical companies in launching and managing their products, encompassing market access, pricing, patient services, and more.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eversana

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eversana's sourcing from India is highly concentrated, with the top five products accounting for 85.7% of the total import value. This significant concentration suggests a strategic focus on specific high-demand products, potentially leveraging favorable pricing and quality from Indian suppliers. However, such dependency may pose risks related to supply chain disruptions or regulatory changes affecting these key products.

2Supply Chain Resilience

Eversana's supply chain resilience is bolstered by its diversified supplier base, comprising 20 unique Indian suppliers. This diversity mitigates risks associated with single-source dependency. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a strategic approach to sourcing ready-to-market products. Additionally, Eversana's global network and integrated services enhance its ability to adapt to supply chain challenges.

3Strategic Implications

Eversana's concentrated sourcing strategy positions it to negotiate favorable terms with key Indian suppliers, potentially enhancing its competitive edge in the U.S. market. For Indian exporters, aligning with Eversana's product focus and quality standards presents an opportunity to establish long-term partnerships, particularly in the high-demand therapeutic areas identified.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing these imports includes the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets standards for drug safety, efficacy, and labeling. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including those imported from foreign markets.

2Import Licensing & GMP

Importers of pharmaceutical products into the U.S. must ensure that their foreign suppliers are registered with the FDA and that their products are listed appropriately. Good Manufacturing Practice (GMP) certification is crucial; the FDA recognizes certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must also obtain wholesale distribution authorization to legally distribute pharmaceutical products within the U.S.

3Quality & Labeling

Eversana — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eversana's focus on importing products in the cardiovascular, medical devices & diagnostics, and antibiotics therapeutic categories aligns with market demand for these essential treatments. The significant import values of heparin, enoxaparin, and vancomycin indicate a strategic emphasis on high-demand, life-saving medications. This product strategy positions Eversana to meet critical healthcare needs while leveraging favorable sourcing opportunities.

2Sourcing Profile

Eversana's sourcing strategy emphasizes finished pharmaceutical formulations, particularly in the cardiovascular and antibiotic categories. This approach allows the company to offer ready-to-market products, reducing time to market and ensuring compliance with U.S. regulatory standards. India's established pharmaceutical manufacturing capabilities make it a key partner in this sourcing strategy.

3Market Positioning

Eversana serves a diverse segment of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and government tenders. Its comprehensive commercialization services enable pharmaceutical companies to effectively reach various healthcare providers and patients, ensuring broad distribution and access to essential medications.

Seller's Guide — How to Become a Supplier to Eversana

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Eversana, particularly those offering high-quality finished pharmaceutical formulations in the cardiovascular and antibiotic categories. Eversana's diversified supplier base and focus on specific therapeutic areas create avenues for additional suppliers to meet market demand and establish long-term partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply Eversana and the U.S. market must ensure their products are FDA-approved and manufactured in compliance with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Products must also meet FDA labeling requirements, including accurate and informative labeling in English. Establishing a relationship with Eversana may involve demonstrating product quality, regulatory compliance, and alignment with Eversana's therapeutic focus areas.

3How to Approach

Indian exporters should initiate contact with Eversana by presenting their product portfolios, emphasizing compliance with FDA regulations and GMP standards. Participating in industry trade shows and conferences can facilitate networking opportunities. Understanding Eversana's specific therapeutic focus areas and aligning product offerings accordingly will enhance the potential for partnership. Engaging in discussions about regulatory filing strategies and timelines will be crucial for establishing a successful collaboration.

Frequently Asked Questions — Eversana

What products does Eversana import from India?

Eversana imports 12 pharmaceutical products across 9 categories. Top imports: Heparin ($13.4M), Enoxaparin ($3.5M), Syringe ($3.5M), Vancomycin ($2.1M), Sodium ($1.1M).

Who supplies pharmaceuticals to Eversana from India?

Eversana sources from 20 verified Indian suppliers. The primary supplier is Zydus Lifesciences Limited (37.6% of imports, $133.6M).

What is Eversana's total pharmaceutical import value?

Eversana's total pharmaceutical import value from India is $27.6M, based on 552 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eversana focus on?

Eversana imports across 9 categories. The largest: Cardiovascular (61.8%), Medical Devices & Diagnostics (12.7%), Antibiotics (9.8%).

Get Full Eversana Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.